Esatenolol

Esatenolol

SCHEMBL4363

CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1

The experimentally established mechanism targets of Esatenolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 known ✓ P08588 4/20 1.00
ADRB2 P07550 4/20 1.00
LMNA P02545 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
ADRA1A P35348 2/20 1.00
CYP1A2 P05177 2/20 1.00
TSHR P16473 2/20 1.00
CNR1 P21554 1/20 1.00
ADRA1D P25100 1/20 1.00
ADRA1B P35368 1/20 1.00
KDM4E B2RXH2 1/20 1.00
GLA P06280 1/20 1.00
CYP3A4 P08684 1/20 1.00
NFKB1 P19838 1/20 1.00
THPO P40225 1/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00
PTGS1 P23219 1/20 0.63
SLC6A2 P23975 1/20 0.63
CYP2D6 P10635 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Atenolol SCHEMBL18120 1.00 ADRB2 (1.00) ADRB2ADRB1LMNATDP1ADRA1A
Atenolol SCHEMBL4362 1.00 ADRB2 (1.00) ADRB2ADRB1LMNATDP1ADRA1A
Atenolol SCHEMBL6509830 1.00 ADRB2 (1.00) ADRB2ADRB1LMNATDP1ADRA1A
Atenolol SCHEMBL16165106 0.99 ADRB2 (0.97) ADRB2ADRB1LMNATDP1ADRA1A
Atenolol SCHEMBL1155317 0.99 ADRB2 (0.97) ADRB2ADRB1LMNATDP1ADRA1A
Atenolol SCHEMBL27238468 0.96 ADRB2 (0.93) ADRB2ADRB1LMNATDP1ADRA1A
Atenolol SCHEMBL119797 0.96 ADRB2 (0.93) ADRB2ADRB1LMNATDP1ADRA1A
Atenolol SCHEMBL27238436 0.95 ADRB2 (0.90) ADRB2ADRB1LMNATDP1ADRA1A
Atenolol SCHEMBL2325992 0.94 ADRB2 (0.88) ADRB2ADRB1LMNATDP1ADRA1A
Atenolol SCHEMBL5796984 0.94 ADRB2 (0.88) ADRB2ADRB1LMNATDP1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 46524 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
WO-2026106917-A1 EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL BioPhysics Pharma, Inc. (US) 2026-05-21 WO claimed
WO-2026090164-A1 COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN KALLYOPE, INC. (US) 2026-04-30 WO claimed
EP-4727545-A2 COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS Neurawell Therapeutics (US) 2026-04-22 EP claimed
US-12605345-B2 Transdermal drug delivery system BioPhysics Pharma, Inc. (US) 2026-04-21 US claimed
EP-4724049-A1 MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF Catalent Ontario Limited (CA) 2026-04-15 EP claimed
US-12599567-B2 Method for preparing a veterinary medicament dosage with inks and a veterinary medicament dosage obtainable by the method CURIFYLABS OY (FI) 2026-04-14 US claimed
US-20260076953-A1 METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2026-03-19 US claimed
EP-4705765-A2 BUCCAL CELL DIAGNOSIS OF RISK IN FAMILIAL ARRHYTHMIA SYNDROMES Beth Israel Deaconess Medical Center, Inc. (US) 2026-03-11 EP claimed
CN-121577794-A Method for simultaneously detecting atenolol and digoxin in cell incubation liquid 成都华西海圻医药科技有限公司 2026-02-27 CN claimed
WO-1982003009-A1 NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR UNIV KENTUCKY RES FOUND (US) 1982-09-16 WO claimed
EP-0049842-A2 Substituted enantholactam derivatives, a process for the preparation and a pharmaceutical composition useful in the treatment of hypertension comprising the same, and intermediates MERCK & CO. INC. (US) 1982-04-21 EP claimed
EP-0049505-A2 Substituted caprolactam derivatives, a process for preparing and a pharmaceutical composition containing the same, and intermediates MERCK & CO. INC. (US) 1982-04-14 EP claimed
EP-0046289-A2 Substituted enantholactam derivatives as antihypertensives, a process for preparing and a pharmaceutical composition containing them, and intermediates MERCK & CO. INC. (US) 1982-02-24 EP claimed
EP-0046291-A2 Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates MERCK & CO. INC. (US) 1982-02-24 EP claimed
US-4303637-A Medication indicated for ocular hypertension ALZA CORPORATION (US) 1981-12-01 US claimed
EP-0037622-A2 Drug delivery insert for controlled ocular therapy ALZA CORPORATION (US) 1981-10-14 EP claimed
EP-0036138-A2 Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide MERCK & CO. INC. (US) 1981-09-23 EP claimed
US-4281654-A Drug delivery system for controlled ocular therapy ALZA CORPORATION (US) 1981-08-04 US claimed
US-4256108-A Microporous-semipermeable laminated osmotic system ALZA CORPORATION (US) 1981-03-17 US claimed